Chimeric antigen receptor T-cells (CAR-Ts), reviewed last week, are a powerful new weapon for oncologists to use in their fight against cancer. These engineered T-cells are designed to home in on and kill malignant cells, and have proven highly effective at treating...
THE FLASH OF THE FIRST CAR-T Last week’s much anticipated FDA approval of the first chimeric antigen receptor T-cell (CAR-T) therapy for acute lymphocytic leukemia hails as the first gene therapy on the US market. Classified as a “cell-based gene therapy,” Novartis’...
The Race Is On Our last WEEKLY—Hacking the Immune Response—unveiled the science behind CAR-T and TCR, two immunotherapies under the microscope of the mainstream press. The well-deserved media attention highlights the ability of these “living drugs” to recognize and...
HBO shines light on novel immunotherapies HBO’s Vice news program selected a few promising technologies from the immunotherapy pipeline to feature in its Killing Cancer episode. Vice’s heartrending human interest stories illustrated the potential of three...
DISSOLUTION OF CANCER CLUB WANTED If you are part of the “cancer club,” it means that you are personally familiar with the devastation cancer causes. Far too many of us are members, whether it is through supporting loved ones with cancer or enduring and persevering...
About Biotech Primer
From startups to the Fortune 500, we train employees at companies of all sizes. We offer customized, in-house courses and open enrollment classes. Visit Biotech Primer for more information.
